{"drugs":["Guanidine Hydrochloride"],"mono":{"0":{"id":"265370-s-0","title":"Generic Names","mono":"Guanidine Hydrochloride"},"1":{"id":"265370-s-1","title":"Dosing and Indications","sub":{"0":{"id":"265370-s-1-4","title":"Adult Dosing","mono":"<b>Eaton-Lambert syndrome:<\/b> 10 to 15 mg\/kg\/day ORALLY in 3 or 4 divided doses; titrate gradually up to 35 mg\/kg\/day or to intolerable side effects "},"1":{"id":"265370-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy in pediatric patients have not been established "},"3":{"id":"265370-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Eaton-Lambert syndrome<br\/>"}}},"3":{"id":"265370-s-3","title":"Contraindications\/Warnings","sub":[{"id":"265370-s-3-9","title":"Contraindications","mono":"allergy or intolerance to guanidine <br\/>"},{"id":"265370-s-3-10","title":"Precautions","mono":"<ul><li>bone marrow suppression, dose-related and with fatalities, may occur; monitoring recommended; discontinue therapy if bone marrow suppression occurs<\/li><li>behavior disorders have been reported<\/li><li>concomitant use with drugs causing bone marrow suppression should be avoided<\/li><li>gastrointestinal adverse effects have been reported and may preclude use<\/li><li>renal function, changes may occur; monitoring recommended<\/li><\/ul>"},{"id":"265370-s-3-11","title":"Pregnancy Category","mono":"Guanidine: Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"265370-s-3-12","title":"Breast Feeding","mono":"Guanidine: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"265370-s-4","title":"Drug Interactions","sub":{"1":{"id":"265370-s-4-14","title":"Major","mono":"<ul><li>Bupropion (theoretical)<\/li><li>Donepezil (theoretical)<\/li><\/ul>"}}},"5":{"id":"265370-s-5","title":"Adverse Effects","mono":"<b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Atrial fibrillation<\/li><li><b>Hematologic:<\/b>Anemia, Leukopenia, Myelosuppression, Thrombocytopenia<\/li><li><b>Hepatic:<\/b>Liver function tests abnormal<\/li><li><b>Psychiatric:<\/b>Psychotic disorder<\/li><li><b>Renal:<\/b>Interstitial nephritis, acute, Interstitial nephritis, chronic, Serum creatinine raised, Tubular necrosis, acute, Uremia<\/li><\/ul>"},"6":{"id":"265370-s-6","title":"Drug Name Info","sub":{"2":{"id":"265370-s-6-19","title":"Class","mono":"<ul><li>Central Nervous System Agent<\/li><li>Cholinesterase Inhibitor<\/li><\/ul>"},"3":{"id":"265370-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"265370-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"265370-s-7","title":"Mechanism Of Action","mono":"Following a nerve impulse, guanidine hydrochloride enhances acetylcholine release and also slows the rate of depolarization and repolarization of muscle cell membranes, which reduces muscle weakness and fatigability.<br\/>"},"10":{"id":"265370-s-10","title":"Monitoring","mono":"<ul><li>improvement in fatigue and muscle weakness indicates efficacy<\/li><li>CBC with differential at baseline and frequently during therapy<\/li><li>urine examinations and serum creatinine measurements<\/li><\/ul>"},"11":{"id":"265370-s-11","title":"How Supplied","mono":"<b>Generic<\/b><br\/>Oral Tablet: 125 MG<br\/>"},"13":{"id":"265370-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to report signs or symptoms of bone marrow suppression (anemia, leukopenia, thrombocytopenia).<\/li><li>Instruct patient to report signs or symptoms of new onset or worsening renal dysfunction.<\/li><li>Warn patient to immediately report signs or symptoms of emotional lability, a psychotic state, confusion, mood changes, or hallucinations.<\/li><li>Drug may cause paresthesias, nervousness, irritability, tremors, flushing, rash, sweating, palpitations, tachycardia, and hypotension.<\/li><li>Counsel patient to report severe gastrointestinal symptoms (dry mouth, gastric irritation, anorexia, nausea, diarrhea, abdominal cramping).<\/li><\/ul>"}}}